Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba, +249

The Lancet

Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning

Lye Mun Tho, M. Glegg, J R Paterson, +4

International Journal of Radiation Oncology*Biology*Physics

Inverse PlanningRadiation TherapyGastrointestinal OncologyMedicineGastroenterology +7

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer

Ross Carruthers, Lye Mun Tho, Jennifer R. Brown, +3

Colorectal Disease

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon, +36

The Lancet Oncology

Met AmplificationMedicinePathologyInsight 2Cancer Treatment +6

INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in <i>MET</i> -Amplified NSCLC and First-Line Osimertinib Resistance

Egbert F. Smit, Christophe Dooms, Jo Raskin, +15

Future Oncology

Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis

Lye Mun Tho, Silvana Libertini, R. Rampling, +2

Oncogene

PhotocarcinogenesisDermatologyMedicineCell SignalingTumor Microenvironment +2

Morphine use for cancer pain: A strong analgesic used only at the end of life? A qualitative study on attitudes and perceptions of morphine in patients with advanced cancer and their caregivers

Julia Ho, Hayati Yaakup, Grace Sook Hoon Low, +3

Palliative Medicine

Lung Cancer in Malaysia

Pathmanathan Rajadurai, Soon Hin How, Chong Kin Liam, +3

Journal of Thoracic Oncology

MedicineBronchial NeoplasmPulmonary BlastomaOncologyRadiation Oncology +2

The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy

Scott Hanvey, M. McJury, Lye Mun Tho, +7

Radiation Oncology

Tepotinib + osimertinib for <i>EGFR </i>mutant<i> (EGFR</i>m) NSCLC with <i>MET</i> amplification (<i>MET</i>amp) after first-line (1L) osimertinib.

Daniel Shao-Weng Tan, Tae Min Kim, Valentina Guarneri, +17

Journal of Clinical Oncology

Signal TransductionEgfrm NsclcMedicineReceptor Tyrosine KinasePharmacology +12